High intensity interval training to improve insulin sensitivity in type 2 diabetes
Effects of High Intensity Interval Training on Skeletal Muscle Insulin Sensitivity in Type 2 Diabetes Patients
This study tests if high intensity interval training can help people with type 2 diabetes improve their insulin sensitivity and manage their blood sugar levels better.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 36 (estimated) |
| Ages | 45 Years to 75 Years |
| Sex | All |
| Sponsor | Finis Terrae University Academic / other |
| Locations | 1 site (Santiago) |
| Trial ID | NCT06688461 on ClinicalTrials.gov |
What this trial studies
This study investigates the effects of high intensity interval training (HIIT) on insulin sensitivity in patients with type 2 diabetes mellitus (T2DM). It focuses on how exercise can enhance glucose disposal in skeletal muscle, which is often impaired in T2DM patients due to insulin resistance. Participants aged 45 to 75 with a diagnosis of T2DM will engage in a structured exercise program while being monitored for changes in insulin sensitivity and plasma glucose levels. The study aims to understand the relationship between exercise, insulin sensitivity, and fat accumulation in the liver.
Who should consider this trial
Good fit: Ideal candidates are adults aged 45 to 75 with a diagnosis of type 2 diabetes for 1 to 5 years and stable on specific diabetes medications.
Not a fit: Patients with type 1 diabetes, severe comorbidities, or those on certain diabetes medications may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly improve insulin sensitivity and glucose regulation in patients with type 2 diabetes.
How similar studies have performed: Previous studies have shown that exercise interventions can improve insulin sensitivity in type 2 diabetes, supporting the potential effectiveness of this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Participants are able to provide signed and dated written informed consent prior to any study specific procedures * Aged ≥ 45 and ≤ 75 years * BMI: 25-35 kg/m2 * Diagnosed as T2DM patients for at least 1 year and not longer than 5 years * HbA1c ≥ 6.5% and ≤ 8.5% * Fasting blood glucose \<130 mg/dL * Women are post-menopausal (\>1 year cessation of menses), * Being stable on medication use of metformin and/or sulfonylurea derivatives for the previous 3 months or more and other medication naïve. Exclusion Criteria: * Type 1 diabetes * Patients with congestive heart failure and and/or severe renal and or liver insufficiency * Contraindications for MRI/MRS examination * Active diabetic foot * Polyneuropathy or retinopathy * Signs of active liver or kidney dysfunction * BMI \>35 kg/m2 * Exogeneous insulin therapy * Use of antidiabetic medication other than metformin or sulfonylurea derivatives treatment within 3 months before screening * Use of SGLT2 inhibitors * Unstable body weight (variations \>5kg in the last 3 months) * Ongoing weight loss diet or use of weight loss agents * Uncontrolled hypertension * Engagement in regular exercise program or any other medical condition that will impede the safe performance of the experiments
Where this trial is running
Santiago
- Finis Terrae University — Santiago, Chile (Recruiting)
Study contacts
- Principal investigator: Rodrigo Mancilla, PhD — Finis Terrae University
- Study coordinator: Rodrigo Mancilla, PhD
- Email: rmancilla@uft.cl
- Phone: +56953676588
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.